ISA reports highlights of randomized Phase 2 cancer vaccine trial in head & neck cancer

The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy

ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

Professor Melief to receive 2022 SITC Pedro J. Romero Award

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

ISA106 – SLP therapeutic for COVID-19